A Trial Investigating the Safety, Tolerability, Pharmacokinetics (the Exposure of the Trial Drug in the Body) and Pharmacodynamics (the Effect of the Investigated Drug on the Body) of Insulin 287 in Subjects With Type 2 Diabetes - Trial NCT02964104
Access comprehensive clinical trial information for NCT02964104 through Pure Global AI's free database. This Phase 1 trial is sponsored by Novo Nordisk A/S and is currently Completed. The study focuses on Diabetes,Diabetes Mellitus, Type 2. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Novo Nordisk A/S
Timeline & Enrollment
Phase 1
Nov 15, 2016
Dec 12, 2017
Primary Outcome
Number of treatment emergent adverse events (TEAE)
Summary
This trial is conducted in Europe. The aim of the trial is to investigate the safety,
 tolerability, pharmacokinetics (the exposure of the trial drug in the body) and
 pharmacodynamics (the effect of the investigated drug on the body) of insulin 287 in subjects
 with type 2 diabetes.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT02964104
Non-Device Trial